Jefferies Financial Group Inc. Invests $4.90 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

Jefferies Financial Group Inc. acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 202,630 shares of the company's stock, valued at approximately $4,900,000. Jefferies Financial Group Inc. owned approximately 0.09% of Hims & Hers Health at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the period. Renaissance Technologies LLC raised its holdings in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after purchasing an additional 40,447 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded up $0.08 during mid-day trading on Wednesday, hitting $53.44. The stock had a trading volume of 19,561,447 shares, compared to its average volume of 19,641,500. The company's 50 day moving average is $38.78 and its 200-day moving average is $35.51. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The company has a market cap of $11.96 billion, a PE ratio of 121.46 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's revenue was up 110.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.05 EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Irene Becklund sold 2,203 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total value of $63,402.34. Following the completion of the sale, the insider now directly owns 8,007 shares of the company's stock, valued at $230,441.46. This represents a 21.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.22, for a total transaction of $697,407.82. Following the completion of the transaction, the chief financial officer now owns 113,816 shares in the company, valued at approximately $6,853,999.52. This represents a 9.24% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 606,704 shares of company stock worth $24,621,075. 13.71% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

HIMS has been the topic of a number of research reports. Bank of America boosted their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Morgan Stanley reduced their price objective on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 29th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Truist Financial cut their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.